A phase III comparison of radiation therapy with or without recombinant β-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 5, 2002, Pages 1173-1179

  Bradley, Jeffrey D ^a,j   Scott, Charles B ^b   Paris, Kristie J ^c   Demas, William F ^d   Machtay, Mitchell ^e   Komaki, Ritsuko ^f   Movsas, Benjamin ^g   Rubin, Philip ^h   Sause, William T ⁱ  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^d AKRON CITY HOSPITAL   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ LDS HOSPITAL   (United States)

^j Radiation Oncology Center   (United States)

more..

Author keywords

Interferon; Non small cell lung cancer; Radiation therapy

Indexed keywords

CELLS; INTERFERONS; PATIENT TREATMENT; SURGERY; TOXICITY; TUMORS;

SURVIVAL RATES;

RADIOTHERAPY;

INTERFERON BETA SERINE;

ACUTE TOXICITY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; RADIOTHERAPY;

EID: 0036534719     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02797-3     Document Type: Article

References (27)

1. Cancer statistics 2001
2. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small cell lung cancer
3. Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small cell lung cancer treated with radiation therapy
4. Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer
5. Potency stability of recombinant (Serine-17) human interferon-beta
6. The long-term stability of recombinant (serine-17) human interferon-beta
7. Interferon-beta-1b (Betaseron); A model for hydrophobic therapeutic proteins
8. On a test of whether one of two random variables is stochastically larger than the other
9. Nonparametric estimation from incomplete observations
10. Evaluation of survival data and two new rank order statistics arising in its consideration
11. Recursive partitioning analysis of 1999 patients with locally-advanced non-small-cell lung cancer (LA-NSCLC); Identification of five groups with different survival
12. How interferons fight disease
13. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
14. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter randomized, double-blind placebo-controlled trial
15. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
16. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis; Final outcome of the randomized controlled trial
17. 2-M phase of the cell cycle
18. Potentiation of radiation injury by interferon
19. Radiosensitization of human bronchogenic carcinoma cells by interferon beta
20. Phase I evaluation of a synthetic mutant of B-interferon
21. Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial
22. Double-blind randomized phase I study of the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously
23. The contributions of cyclooxygenase-2 to tumor angiogenesis
24. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
25. Aspirin-like molecules that covalently inactivate cyclooxygenase-2